Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$ 

Gen	ex Power Limited	
ABN		
18 1	52 098 854	
We (t	he entity) give ASX the following	information.
	: <b>1 - All issues</b> ust complete the relevant sections (attach	sheets if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	N/A
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	N/A

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

- 3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1. Issue of 1 unsecured Convertible Note to ARENA in the amount of \$121,276 pursuant to the terms of the funding agreement between ARENA and Genex as announced to the ASX on 18 December 2015 (1st ARENA Agreement); and
- 2. Issue of 1 unsecured Convertible Note to ARENA in the amount of \$26,503 pursuant to the terms of the funding agreement between ARENA and Genex as announced to the ASX on 17 November 2017 (2<sup>nd</sup> ARENA Agreement).

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	1 & 2. No
5	Issue price or consideration	1 & 2. Nil until conversion or redemption
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>Issued upon receipt of the eighteenth instalment under the 1<sup>st</sup> ARENA Agreement; and</li> <li>Issued upon receipt of the first instalment under the 2<sup>nd</sup> ARENA Agreement.</li> </ol>
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	23 November 2017
6c	Number of *securities issued without security holder approval under rule 7.1	9,673,806
6d	Number of *securities issued with security holder approval under rule 7.1A	0

<sup>+</sup> See chapter 19 for defined terms.

6	ie .	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	0
6	of	Number of *securities issued under an exception in rule 7.2	16,173,750 shares pursuant to exception 4
6	g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6	bh	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6	oi .	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 Capacity: 35,915,921 7.1A Capacity: 30,393,151 Total 7.1 & 7.1A Capacity: 66,309,072
	_		-
7	,	<sup>+</sup> Issue dates	1 & 2. 19 April, 2018
		Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
		Cross reference: item 33 of Appendix 3B	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
Number 303,931,514	Fully Paid Ordinary
	Shares (FPOS)

<sup>+</sup> See chapter 19 for defined terms.

9	Number and +class of all +securities not quoted on ASX	<u>Number</u>	<u>Class</u>
	(including the *securities in section 2 if applicable)	8,500,000	Options exercisable at \$0.25 each and expiring 7 February 2019;
		5,000,000	Options exercisable
		(1,666,667 vested)	at \$0.25 each and expiring 6 August 2020 with various vesting milestones attached;
		2,400,000	Options exercisable
		(800,000 vested)	at \$0.25 each and expiring 2 September 2021 with various vesting
		15,500,000	milestones attached; Options exercisable at \$0.34 each and expiring 17 January 2022;
		4,850,000	Options exercisable
		(nil vested)	at \$0.40 each and expiring 13 February 2023 with various
		\$3,200,979	vesting milestones attached; 18 Unsecured Convertible Notes issued to ARENA –
		<u>\$26,503</u>	equating to 16,004,895 shares assuming all 18 convertible notes were fully converted at \$0.20 per share under the 1st ARENA Agreement. 1 Unsecured Convertible Note issued to ARENA – equating to 92,506 shares assuming the convertible note was fully converted at the floor price of \$0.2865 per share under the 2nd ARENA Agreement.

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
Part	2 - Pro rata issue	
11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the <sup>+</sup> securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their	
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B New issue announcement

	_	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?		
33	<sup>+</sup> Issue	e date		
		Quotation of securition of securition of securition are application and are applications.		
34	Type (tick o	of <sup>+</sup> securities one)		
(a)		+Securities described in Part 2		
(b)			d of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible	
Entit	ies tha	at have ticked box 34(a)		
Additional securities forming a new class of securities				
Tick to docum		e you are providing the informati	on or	
35			securities, the names of the 20 largest holders of the number and percentage of additional *securities	
36			securities, a distribution schedule of the additional ober of holders in the categories	
37		A copy of any trust deed for th	ne additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	287,757,764	
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	16,173,750 – exception 4	
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>		
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0	
"A"	303,931,514	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

0. 0.01.1		
Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	45,589,727	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<ul> <li>Insert number of †equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	6,350,000 Options  3,323,806 Shares (these Shares have not been issued but assumes the ARENA Convertible Notes referred to in the Appendix 3B's dated 24.10.17, 01.11.17; 12.12.17, 19.02.18, 20.03.18 are converted in full at \$0.20 per Share)	
"C"	9,673,806	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	45,589,727	
Note: number must be same as shown in Step 2		
Subtract "C"	9,673,806	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	35,915,921	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	303,931,514	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	30,393,151	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	0	

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	30,393,151
Note: number must be same as shown in Step 2	
Subtract "E"	0
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	30,393,151
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.